Recombinant Human AGR3 Protein (HEK293)，His

AGR3 (anterior gradient 3) is a protein that has garnered significant attention in the field of cancer research due to its potential role in tumorigenesis and the progression of various malignancies, particularly breast cancer. Originally identified as a developmental protein, AGR3 is thought to be involved in the regulation of cell proliferation, differentiation, and survival. Its expression is often upregulated in cancerous tissues, suggesting that it may function as a biomarker for disease progression. Moreover, AGR3 has been implicated in the modulation of the ER (estrogen receptor) signaling pathway, which plays a critical role in hormone-dependent cancers. Research has shown that AGR3 can influence the response of tumors to hormonal therapies, making it a target of interest for therapeutics aimed at overcoming treatment resistance. The study of recombinant AGR3 proteins, including their structural and functional characteristics, has advanced our understanding of its precise biological roles, interactions with other cellular proteins, and potential as a therapeutic target. This research trajectory not only contributes to basic science but also has important implications for developing more effective strategies for cancer diagnosis and treatment, highlighting AGR3's relevance in the search for novel cancer therapies. Through ongoing investigations into AGR3, we aim to unravel its mechanisms in tumor biology, which may lead to innovative approaches for tackling resistant cancer forms and improving patient outcomes.